The award-winning clinical skincare brand, MATTER OF FACT, has announced its first-ever multi-channel retail expansion. The brand’s products, formulated by founder and CEO Paul Baek, are now available on Sephora.com and will be hitting the shelves in 270 Sephora brick-and-mortar locations across the United States starting August 25, 2023.
MATTER OF FACT‘s journey began fifteen years ago when Baek, a professional K-Pop musician at the time, sought gentle yet effective solutions for his acne-prone skin. His deep interest in skincare formulation led him to develop potent active ingredients that delivered powerful results without adverse reactions.
The brand’s official launch on Sephora.com and in Sephora stores includes a range of innovative products. One such product is the Wrinkle + Texture Concentrate, a first-of-its-kind, patent-pending treatment that combines retinol, Vitamin C, and azelaic acid into one formula. This product, launched in July 2023, is clinically proven to visibly improve multiple signs of…
aging including wrinkles, dark spots, skin texture, and tone. MATTER OF FACT’s approach to skincare is unique, with a strong emphasis on its clinical commitment. The brand aims to provide clients with a clear understanding of what concerns a product can realistically address, in what time frame, and to what degree.
They run thousands of hours of testing on their products to ensure a data-rich, verifiable approach. Their clinical commitment comprises three key components: an unbiased approach, reflective of the real world, and robust measurement of results. Tests are administered by independent, third-party labs to minimize bias.
Products are tested on a diverse range of skin tones using the Fitzpatrick Phototypes Scale I-VI to ensure diversity and representation in their clinical tests. Results are measured in three different ways to substantiate strong claims for their products.
Launched in 2021, MATTER OF FACT focuses on the development of innovative products made with clinically proven ingredients formulated with patent-pending technologies. This allows for a first-of-its-kind combination therapy, multi-benefit user experience. A rigorous commitment to research and development…
Discussion
0 Comments
No comments yet
Start the conversation
Share your take on this story and help shape the discussion.
Sign in to join the discussion.